When children develop methicillin-resistant Staphylococcus aureus (MRSA), a dangerous bacterial infection, vancomycin has long been the go-to treatment, but new research shows hospitals are diversifying their antibiotic options. A comprehensive eight-year analysis of pediatric MRSA treatment across 40 children's hospitals reveals that while vancomycin remains the primary therapy in over 50% of cases, doctors are increasingly reaching for alternative antibiotics, particularly ceftaroline (brand name Teflaro), when facing treatment challenges. What's Driving the Shift Away From Vancomycin? For decades, vancomycin has been the standard first-line treatment for MRSA in children. However, the new data presented at IDWeek 2025 in Atlanta shows a meaningful change in prescribing patterns. Sirey Zhang, MD, a pediatric resident at the University of Utah who led the research, explained the reasoning behind this evolution. "There are new options that are out there for treating MRSA in children. The gut reaction to go to vancomycin is always very valid and useful in most cases. But when we have growing resistance, adverse drug reactions, or persistent bacteremia infection despite vancomycin, it's nice to know that there are a lot of alternatives out there that are coming into view," Dr. Zhang said. The study analyzed treatment trends from 2016 through 2024, tracking which antibiotics pediatric hospitals were using to combat MRSA infections. The findings reveal a clear pattern: while vancomycin use remains dominant, clindamycin use has declined significantly, and ceftaroline adoption is accelerating. In some cases, ceftaroline is used alone or combined with vancomycin or daptomycin as salvage therapy for infections that don't respond to initial treatment. How Are Hospitals Treating Resistant MRSA Cases? - Ceftaroline (Teflaro): This newer fifth-generation cephalosporin antibiotic is increasingly used as a first-line option or in combination with other drugs when vancomycin proves ineffective or causes adverse reactions in children. - Daptomycin: Reserved primarily as salvage therapy for refractory cases, this antibiotic is used when standard treatments fail to clear persistent bacterial infections. - Combination Therapy: Some hospitals are using multiple antibiotics together, such as ceftaroline plus vancomycin or daptomycin, to overcome treatment resistance in complicated cases. The variability in treatment approaches across different children's hospitals is notable. Dr. Zhang and his team found significant differences in which antimicrobials different institutions prefer, suggesting there's room for standardization. "It'd be great to sort of compare outcomes, and differences relating to what sorts of treatment regimens are done for MRSA infection. And with this variability, we can definitely look at ways to improve clinical guidelines, care models and streamline that," Dr. Zhang noted. Is Pediatric MRSA Getting Better or Worse? The good news is that MRSA hospitalization rates in children have actually declined over the eight-year study period, which researchers found reassuring. However, there's a concerning caveat: while the overall number of children hospitalized with MRSA has decreased, the number of children requiring intensive care unit (ICU) stays for MRSA infections has remained relatively stable. This means that while fewer children are developing MRSA overall, the infections that do occur tend to be more severe. The proportion of pediatric MRSA patients requiring ICU-level care compared to regular hospital floor care has shifted, suggesting that the infections being treated today are more serious or complicated than in previous years. What Should Parents Know About MRSA Treatment Options? The emergence of alternative antibiotics like ceftaroline represents genuine progress in pediatric infectious disease treatment. Parents whose children are diagnosed with MRSA should understand that their doctors have multiple evidence-based options available, not just vancomycin. If a child experiences adverse reactions to vancomycin, develops a persistent infection despite treatment, or shows signs of antibiotic resistance, newer alternatives exist that may be more effective. The research also highlights why antibiotic stewardship matters. The variability in treatment approaches across hospitals suggests that some institutions may be using more effective regimens than others. As clinical guidelines evolve to incorporate these newer options, outcomes for children with MRSA infections may continue to improve. The key takeaway is that MRSA treatment in children is no longer a one-size-fits-all approach; it's becoming increasingly personalized based on individual patient factors and infection characteristics.
